Comparative Pharmacology
Head-to-head clinical analysis: ENFLURANE versus ISOFLURANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENFLURANE versus ISOFLURANE.
ENFLURANE vs ISOFLURANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enflurane is a volatile halogenated ether that potentiates GABA-A receptor activity, inhibits NMDA receptors, and enhances glycine receptor function, leading to generalized central nervous system depression and anesthesia.
Isoflurane is a general inhalation anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits excitatory receptors such as NMDA and AMPA receptors. It potentiates inhibitory neurotransmission and depresses excitatory neurotransmission, leading to anesthesia, amnesia, and muscle relaxation.
Induction: 0.5-4.5% inspired concentration; Maintenance: 0.5-3% inspired concentration with oxygen/nitrous oxide; via inhalation.
Induction: 1-3% in oxygen or oxygen/nitrous oxide mixture via inhalation; Maintenance: 0.5-2% in oxygen or oxygen/nitrous oxide mixture via inhalation.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateIsoflurane + Torasemide
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Torasemide."
Clinical Note
moderateIsoflurane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Etacrynic acid."
Clinical Note
moderateIsoflurane + Furosemide
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Furosemide."
Clinical Note
moderateIsoflurane + Bumetanide
Terminal elimination half-life is approximately 4-8 hours in adults; context: prolonged with obesity due to high lipid solubility and storage in adipose tissue.
Terminal elimination half-life is approximately 2.5 to 5 hours. Context: The context-sensitive half-time varies with duration of anesthesia; for short procedures (<1 hour), half-life is about 2-4 minutes, but for prolonged anesthesia, it can be 30-60 minutes due to redistribution from fat stores.
Primarily eliminated by pulmonary excretion as unchanged drug (>90%); less than 5% is metabolized via CYP2E1 to fluoride ions and other metabolites, which are renally excreted.
Primarily eliminated via exhalation through the lungs (>99%). Less than 1% undergoes hepatic metabolism to trifluoroacetic acid and fluoride ions, which are excreted renally.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Bumetanide."